Amsterdam University Medical Center, Departments of General Practice and Medicine for Older Persons, Vrije Universiteit, Amsterdam Public Health Research Institute, Meibergdreef 9, Amsterdam, The Netherlands.
Flevoburen: Geriatric Rehabilitation Centre, Vivium Zorggroep, Almere, The Netherlands.
BMC Geriatr. 2024 Oct 26;24(1):882. doi: 10.1186/s12877-024-05450-y.
The aim of this study was to determine the prevalence of potentially inappropriate medications (PIMs) in nursing home residents across eight countries and investigate differences between residents with and without cognitive impairment, as well as those with and without life expectancy of six months or less.
The study utilized the second edition of the STOPP-Frail criteria to operationalize PIMs in the baseline assessment of nursing home residents participating in the Services and Health for Elderly in Long TERm care (SHELTER) project. The data were collected between 2009 and 2012. The project was conducted in eight countries: Czech Republic, England, Finland, France, Germany, Italy, the Netherlands, and Israel. Cognitive impairment was measured by the cognitive performance scale (CPS). The presence of end-stage disease with a life expectancy of six months or less was recorded. The study included residents aged 60 years or older who underwent a valid medication assessment.
Among the 3,832 eligible residents, 87.9% had at least one PIM. Specifically, 24.3%, 23.5%, 18.8%, and 19.3% of residents had one, two, three, and four or more PIMs, respectively. On average, each person was prescribed 2.16 PIMs. Cognitively impaired residents (n = 1999) had an average of 1.96 PIMs (SD 1.49) per person, while residents with a low CPS score (n = 1783) had an average of 2.40 PIMs (SD 1.57) per person, showing a statistically significant difference (P < 0.001). Similarly, NH residents with life expectancy of six months or less had an average of 1.66 PIMs (SD 1.30), whereas those without had an average of 2.17 PIMs (SD 1.55) (p < 0.001). The average number of PIMs varied across countries, ranging from 3.23 in Finland to 2.15 in the UK (P < 0.001). Anti-platelets and aspirin were the most prescribed PIMs, accounting for over 38.0% of prescriptions.
This study highlights the high prevalence of PIMs among nursing home residents. However, PIMs were somewhat lower in residents with cognitive impairment and life expectancy of six months or less. Efforts must continue to improve the rationale behind prescribing practices in nursing homes.
本研究旨在确定 8 个国家的养老院居民中潜在不适当药物(PIMs)的流行程度,并探讨认知障碍患者与无认知障碍患者、预期寿命不足 6 个月患者与无预期寿命不足 6 个月患者之间的差异。
本研究利用第二版 STOPP-Frail 标准,对参与 Services and Health for Elderly in Long TERm care(SHELTER)项目的养老院居民的基线评估进行 PIMs 的操作化。数据收集于 2009 年至 2012 年期间。该项目在 8 个国家开展:捷克共和国、英国、芬兰、法国、德国、意大利、荷兰和以色列。认知障碍通过认知表现量表(CPS)进行测量。记录存在预期寿命不足 6 个月的终末期疾病。本研究纳入了年龄在 60 岁及以上且接受了有效药物评估的居民。
在 3832 名符合条件的居民中,87.9%至少有一种 PIM。具体而言,分别有 24.3%、23.5%、18.8%和 19.3%的居民各有一种、两种、三种和四种或更多 PIM。平均而言,每个人被开了 2.16 种 PIM。认知障碍居民(n=1999)平均每人有 1.96 种 PIM(SD 1.49),而低 CPS 评分居民(n=1783)平均每人有 2.40 种 PIM(SD 1.57),差异具有统计学意义(P<0.001)。同样,预期寿命不足 6 个月的 NH 居民平均有 1.66 种 PIM(SD 1.30),而预期寿命超过 6 个月的居民平均有 2.17 种 PIM(SD 1.55)(P<0.001)。PIM 的平均数量因国家而异,从芬兰的 3.23 种到英国的 2.15 种(P<0.001)。抗血小板药物和阿司匹林是最常开的 PIMs,占处方的 38.0%以上。
本研究强调了养老院居民中 PIMs 的高流行率。然而,认知障碍和预期寿命不足 6 个月的患者中 PIMs 的数量略低。必须继续努力改善养老院的药物治疗方案的合理性。